MARKET

GILD

GILD

Gilead Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

76.32
+1.61
+2.16%
After Hours: 76.57 +0.25 +0.33% 19:59 07/10 EDT
OPEN
76.10
PREV CLOSE
74.71
HIGH
76.85
LOW
75.52
VOLUME
9.55M
TURNOVER
--
52 WEEK HIGH
85.97
52 WEEK LOW
60.89
MARKET CAP
95.73B
P/E (TTM)
19.62
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 30 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GILD stock price target is 80.87 with a high estimate of 97.00 and a low estimate of 58.00.

EPS

GILD News

More
U.S. Cases Rise to New Record; Disney Opens Parks; Virus Update
Bloomberg · 6m ago
Price of Gold Fundamental Daily Forecast - Yields Not COVID-19 Headlines Driving Price Action
FX Empire · 6h ago
After Remdesivir Trials, Is It Too Late to Buy Gilead Stock?
Motley Fool · 6h ago
Barron’s 2020 Midyear Roundtable: 37 Picks From Our Investment Pros
marketwatch.com · 8h ago
Coronavirus update: Global case tally hits 12.5 million with U.S. accounting for a quarter as death toll starts to rise again
marketwatch.com · 9h ago
Why Gilead Sciences' Successful COVID-19 Results Fell Flat
Motley Fool · 9h ago
Australia's Victoria state records another day of high coronavirus infections
Reuters · 18h ago
HHS allocates Gilead's COVID-19 drug remdesivir to four hardest hit states
Reuters · 23h ago

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About GILD

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
More

Webull offers kinds of Gilead Sciences, Inc. stock information, including NASDAQ:GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.